Zivimox-LP Eye Drop is a sterile ophthalmic suspension combining Loteprednol etabonate 0.5% w/v, a corticosteroid with potent anti-inflammatory properties, and Moxifloxacin 0.5% w/v, a broad-spectrum fluoroquinolone antibiotic. This formulation is indicated for the treatment of ocular inflammatory conditions accompanied by bacterial infections or at risk of secondary bacterial contamination, such as postoperative inflammation following ocular surgery, allergic conjunctivitis, and bacterial conjunctivitis. Loteprednol etabonate acts by inhibiting multiple inflammatory mediators, thereby reducing redness, swelling, and pain, while Moxifloxacin exerts bactericidal activity by inhibiting bacterial DNA gyrase and topoisomerase IV, effectively targeting a wide range of Gram-positive and Gram-negative pathogens. Zivimox-LP Eye Drop should be administered as directed by a healthcare professional, typically instilling one or two drops into the affected eye(s) four times daily. Caution is advised in patients with known hypersensitivity to corticosteroids or fluoroquinolones, and prolonged use may increase the risk of elevated intraocular pressure or secondary infections. It is contraindicated in viral, fungal, or mycobacterial ocular infections. Proper hygiene and adherence to prescribed dosing are essential to optimize therapeutic outcomes and minimize adverse effects.